INTS - Intensity Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

54.11M

Cash

10.5M

Avg Qtr Burn

-2.668M

Short % of Float

0.57%

Insider Ownership

47.37%

Institutional Own.

11.90%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INT230-6 Details Sarcoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 Details Breast cancer	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 w/ Keytruda Details Pancreatic cancer, Colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 Details Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 w/ Yervoy Details Liver cancer, Sarcoma, Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.